Horizon Pharma’s MEDI4945 has potential for subcutaneous dosing and reduced immunogenicity?

Horizon Pharma has licensed the global rights to MEDI4945, a pre-clinical, genetically engineered uricase derivative combined with site-specific PEGylation, from MedImmune, the global biologics research and development arm of AstraZeneca. 

The company said Monday that, under the terms of the agreement, Horizon Pharma will provide MedImmune an upfront cash payment and future payments contingent on MEDI4945 development and sales milestones.

Potential to extend the gout franchise

“In addition to our ongoing development of KRYSTEXXA, the licensing of MEDI4945 gives us the potential to extend the future of our gout franchise,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.  “MEDI4945 provides us with a pre-clinical candidate that, based on initial studies, has the potential for subcutaneous dosing and reduced immunogenicity, which may benefit more patients living with uncontrolled gout.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.